Denali Therapeutics (DNLI) Free Cash Flow (2017 - 2026)
Denali Therapeutics (DNLI) posted quarterly Free Cash Flow of -$133.7 million for Q1 2026, up 2.11% year-over-year from -$130.9 million in Q1 2025, and down 22.25% quarter-over-quarter from -$109.3 million in Q4 2025.
Denali Therapeutics (DNLI) Free Cash Flow (2017 - 2026) Analysis & Trends
Denali Therapeutics (DNLI) has reported Free Cash Flow for 10 consecutive years, with -$133.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Free Cash Flow rose 2.11% year-over-year to -$133.7 million; the TTM figure through Mar 2026 stood at -$419.2 million (down 13.41% YoY), while the FY2025 annual figure was -$422.1 million, down 20.99% from the prior year.
- Free Cash Flow retreated to -$133.7 million in Q1 2026 per DNLI's latest filing, from -$109.3 million in the prior quarter.
- Across five years, Free Cash Flow topped out at -$49.7 million in Q2 2022 and bottomed at -$136.5 million in Q1 2025.
- Historically, Free Cash Flow has averaged -$89.4 million across 5 years, with a median of -$83.7 million in 2024.
- Annual changes were most pronounced in 2023 — Free Cash Flow tumbled 132.77% — and 2024, when it surged 32.19%.
- Denali Therapeutics' Free Cash Flow stood at -$72.4 million in 2022, then tumbled by 54.18% to -$111.6 million in 2023, then increased by 24.97% to -$83.7 million in 2024, then tumbled by 30.59% to -$109.3 million in 2025, then decreased by 22.25% to -$133.7 million in 2026.
- Business Quant data shows DNLI's Free Cash Flow at -$133.7 million in Q1 2026, -$109.3 million in Q4 2025, and -$96.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -389.61 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 437.80 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 477.44 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 292.04 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -95.09 Mn |
| 10 | Denali Therapeutics | 3.90 Bn | 3.90 Bn | 3.51 Mn | -97.81 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -97.81 Mn |
| Jun 30, 2026 | -97.81 Mn |
| Mar 31, 2026 | -133.67 Mn |
| Mar 31, 2026 | -133.67 Mn |
| Dec 31, 2025 | -109.35 Mn |
| Dec 31, 2025 | -109.35 Mn |
| Sep 30, 2025 | -96.64 Mn |
| Sep 30, 2025 | -96.64 Mn |
| Jun 30, 2025 | -79.58 Mn |
| Jun 30, 2025 | -79.58 Mn |
| Mar 31, 2025 | -136.55 Mn |
| Mar 31, 2025 | -136.55 Mn |
| Dec 31, 2024 | -83.73 Mn |
| Dec 31, 2024 | -83.73 Mn |
| Sep 30, 2024 | -53.38 Mn |
| Sep 30, 2024 | -53.38 Mn |
| Jun 30, 2024 | -96.01 Mn |
| Jun 30, 2024 | -96.01 Mn |
| Mar 31, 2024 | -115.77 Mn |
| Mar 31, 2024 | -115.77 Mn |